natgillin/translations-raw huggingface dataset:
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Synjardy opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Tagrisso opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tagrisso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Taltz opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Taltz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Tasermity til behandling af hypofosfatæmi opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tasermity’s benefits are greater than its risks for the treatment of hyperphosphataemia and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Tecfidera opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Tecfidera’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Translarna opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Translarna’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Unituxin opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Unituxin’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Uptravi opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Uptravi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Vantobra opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Vantobra’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Vargatef opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vargatef’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Vaxelis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vaxelis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Vipidia opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Vipidia’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Vokanamet opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vokanamet’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Xadago overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xadago’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Xtandi opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xtandi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Xydalba opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xydalba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zalviso opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zalviso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zavicefta opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zavicefta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zerbaxa opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zerbaxa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zinbryta opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zinbryta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zontivity overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zontivity’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Zykadia opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zykadia’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at forøgelsen af progressionsfri overlevelse var klinisk signifikant, selvom det blev bemærket, at generel længere overlevelse endnu ikke var påvist.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered the increase in progression free survival to be clinically significant although it noted that a benefit in overall survival had not yet been shown.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at kombinationen af fenofibrat og simvastatin er påvist at være effektiv til at forbedre blodets indhold af fedtstoffer.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the combination of fenofibrate and simvastatin has been shown to be effective at improving blood fat levels.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at Odefsey er en alternativ behandlingsform til Eviplera med lignende effektivitet.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that Odefsey is an alternative treatment option to Eviplera with similar effectiveness.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at Ovaleap er påvist at være af en kvalitet, sikkerhed og virkningsprofil, der svarer til GONAL-f.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Ovaleap has been shown to have a comparable quality, safety and efficacy profile to GONAL-f.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at Pheburane er påvist til at være af sammenlignelig kvalitet og til at være bioækvivalent med Ammonaps.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Pheburane has been shown to have comparable quality and to be bioequivalent to Ammonaps.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at Simbrinza var påvist at være mere effektivt end hvert aktivt stof anvendt alene og mindst lige så effektivt som de aktive stoffer givet samtidig som separate øjendråber.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Simbrinza was shown to be more effective than either active substance used alone and at least as effective as the combination of the active substances given as separate eye drops.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konstaterede, at HyQvia giver samme reduktion i antallet af alvorlige bakterielle infektioner som andre immunglobulinprodukter, og at anvendelsen af rekombinant hyaluronidase giver mulighed for meget længere mellemrum mellem infusionerne under huden, dog optræder lokale reaktioner lidt oftere.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that HyQvia produces a similar reduction in the number of serious bacterial infections to that seen with other immunoglobulin products, and using recombinant hyaluronidase allows subcutaneous infusions to be given at much longer intervals, although local reactions are slightly more common.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) vurderede, at fordelene ved Invokana er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Invokana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker bemærkede, at Exviera anvendt i kombination med Viekirax er effektivt til at eliminere hepatitis C-virus genotype 1a og 1b fra blodet med og uden ribavirin.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Exviera used in combination with Viekirax is effective in clearing the hepatitis C virus genotypes 1a and 1b from the blood with and without ribavirin.
Agenturets udvalg for lægemidler til mennesker bemærkede, at undersøgelserne viste, at brug af Lymphoseek resulterede i højere andel af påviste skildvagtlymfeknuder end brug af vitalblåt.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that studies showed that the use of Lymphoseek led to a higher detection rate for sentinel lymph nodes than the use of vital blue dye.
Agenturets Udvalg for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Canigen L4 opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Canigen L4’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Innovax-ILT opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Innovax- ILT’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved UpCard opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that UpCard’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Ageusi Anosmi
Memory impairment Parosmia
ageusi, dysgeusi, paræstesi
ageusia, dysgeusia, paraesthesia
Agglutination af røde blodceller i slanger/sprøjter
Agglutination of red blood cells in the tube/syringe
Aggression
Depression Aggression
Aggression kan også ses i den postiktale fase (tiden umiddelbart efter et anfald), eller som en adfærdsændring, der forekommer som en del af sygdommen.
Aggression may also be present during the postictal period or as a behaviour change which occurs as part of disease itself.
Aggression**, agitation**, vrede**, forvirring**, eufori**, hallucination**, fjendtlighed**, mobilitetsforstyrrelser**, fysiske angreb**
Aggression**, agitation**, anger**, confusional state**, euphoric mood**, hallucination**, hostility**, movement disorder**, physical assault
Aggression*, mordtanker*, panikanfald*, paranoia*, stofmisbrug*, selvmordstanker*, unormal adfærd, vrede, apati, forvirringstilstand, ændring i mentaltilstand, rastløshed
Aggression*, homicidal ideation*, panic attack*, paranoia*, substance abuse*, suicidal ideation*, abnormal behaviour, anger, apathy, confusional state, mental status changes, restlessness
aggression, hallucinationer
aggression, hallucinations
aggression, konfusion, irritabilitet, nervøsitet, rastløshed, ændret humør
Aggression, confusion, irritability, nervousness, restlessness, altered mood;
Aggressiv
Aggressive
aggressiv adfærd,
feeling aggressive,
Aggressiv adfærd, rastløshed
Aggression , feeling restless
Aggressiv adfærd, rastløshed
Aggression, feeling restless
aggressiv adfærd/truende, evt. voldelig adfærd
aggressive behaviour/aggression
aggressiv adfærd/truende, evt. voldelig adfærd desorientering
aggressive behaviour/aggression disorientation
Aggressiv opførsel, humørsvingninger, at se eller høre ting, som i virkeligheden ikke er der (hallucinationer), mani (sindstilstand der er karakteriseret ved episoder af overaktivitet, opstemthed eller irritabilitet), paranoia, selvmordstanker
angry behaviour, mood being affected, seeing or hearing things that are not really there (hallucinations), mania (mental condition characterised by episodes of overactivity, elation or irritability), paranoia, suicidal thoughts
Aggressive og seksuelle (montage) adfærd er også reduceret.
Aggressive and sexual (mounting) behaviours are also reduced.
Aggressivitet
aggression
Aggressivitet *
Aggression
Aggressivitet Agitation Nervøsitet
Agitation Nervousness
aggressivitet, irritabilititet, uro, usædvanlig pirrelighed (hyperexcitabilitet);
aggressiveness, irritability, agitation, hyperexcitability (state of being unusually excitable);
aggressivitet, vredesudbrud, irritabilitet, angst eller forvirring
feeling aggressive, angry, irritable, anxious or confused
agioødem uden kendt årsag hvis du er mere end 3 måneder henne i graviditeten (brug af Rasitrio tidligt i graviditeten bør også undgås – se afsnittet om Graviditet).
angioedema without any known cause. if you are more than 3 months pregnant. (It is also better to avoid Rasitrio in early pregnancy – see Pregnancy section).
Agitation Depression Insomni Humørsvingninger Angst
Agitation Depression Insomnia Mood swings Anxiety
Agitation Konfusion Angst Mareridt Søvnløshed Depression
Agitation Confusion Anxiety Nightmares Insomnia Depression Hallucinations
Agitation Nervøsitet
Agitation Nervousness
Agitation og beslægtede symptomer* (såsom irritabilitet og rastløshed)
Agitation and related symptoms* (such as irritability and restlessness)
Agitation ved skizofreni og bipolær lidelse type I med ABILIFY injektionsvæske, opløsning
Agitation in schizophrenia and Bipolar I Disorder with ABILIFY solution for injection
Agitation, amnesi, ataksi, unormal koordination, kramper, abnorm tankevirksomhed, tremor‡
agitation, amnesia, ataxia, coordination abnormal, convulsions, thinking abnormal, tremor
agitation, depression, angst
agitation, depression, anxiety
Agitation, insomni
Agitation, insomnia
agitation, konfusion, depression
agitation, confusion, depression
agitation, nervøsitet
agitation, nervousness
agitation, vrede, aggressiv opførsel, adfærdsforstyrrelse, koncentrationsbesvær, følelsesmæssig ustabilitet, besvimelse, følelse af angst eller nervøsitet, følelse af kulde, en følelse af forvirring, følelse af rastløshed, følelse af søvnighed, manglende interesse eller
agitation, anger, aggressive behaviour, behaviour disorder, difficulty concentrating, emotional instability, fainting, feeling anxious or nervous, feeling cold, feeling confused, feeling of
agitation, vrede, aggressiv opførsel, adfærdsforstyrrelse, koncentrationsbesvær, følelsesmæssig ustabilitet, besvimelse, følelse af angst eller nervøsitet, følelse af kulde, en følelse af forvirring, følelse af rastløshed, følelse af søvnighed, manglende interesse eller opmærksomhed, humør ændringer, smerter, dårlig søvn kvalitet, gå i søvne, selvmordsforsøg, problemer med at sove, usædvanligedrømme, ønske om at skade dig selv,
agitation, anger, aggressive behaviour, behaviour disorder, difficulty concentrating, emotional instability, fainting, feeling anxious or nervous, feeling cold, feeling confused, feeling of restlessness, feeling sleepy, lack of interest or attention, mood changes, pain, poor quality sleep, sleepwalking, suicide attempt, trouble sleeping, unusual dreams, wanting to harm yourself,
agitation, vrede, aggressiv opførsel, adfærdsforstyrrelse, koncentrationsbesvær, følelsesmæssig ustabilitet, besvimelse, følelse af angst eller nervøsitet, følelse af kulde, følelse af forvirring, følelse af rastløshed, følelse af søvnighed, manglende interesse eller opmærksomhed, humør ændringer, smerter, dårlig søvn kvalitet, gå i søvne, selvmordsforsøg, problemer med at sove, usædvanligedrømme, ønske om at skade dig selv,
agitation, anger, aggressive behaviour, behaviour disorder, difficulty concentrating, emotional instability, fainting, feeling anxious or nervous, feeling cold, feeling confused, feeling of restlessness, feeling sleepy, lack of interest or attention, mood changes, pain, poor quality sleep, sleepwalking, suicide attempt, trouble sleeping, unusual dreams, wanting to harm yourself,
Agitationb, irritabilitetb
Agitationb, irritabilityb
Agitstion, amnesi, ataksi, unormal koordination, kramper, abnorm tankevirksomhed, tremor‡
agitation, amnesia, ataxia, coordination abnormal, convulsions, thinking abnormal, tremor
Agitstion, amnesi, ataksi, unormal koordination, kramper, abnorm tankevirksomhed, tremor‡
agitation, amnesia, ataxia, coordination abnormal, convulsions, thinking abnormal,* tremor
AGN-målinger kan anvendes som vejledning ved dosisjustering af glycerolphenylbutyrat og til at bedømme komplians.
AGN measurements may be used to help guide glycerol phenylbutyrate dose adjustment and assess compliance.
Agomelantin udviste en antidepressiv-lignende virkning i dyremodeller for depression (tillært hjælpe- løshedstest, fortvivlelsestest, kronisk lettere stress) samt i modeller med desynkroniseret døgnrytme og modeller forbundet med stress og angst.
Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety.
Agomelatin
Agomelatine
Agomelatin absorberes hurtigt og godt ( 80%) efter oral administration.
Agomelatine is rapidly and well ( 80%) absorbed after oral administration.
Agomelatin adskilte sig ikke fra placebo i to studier, hvor der var assay-følsomhed for det aktive kontrolstof, paroxetin eller fluoxetin.
Agomelatine failed to differentiate from placebo in two trials where the active control, paroxetine or fluoxetine, showed assay sensitivity.
Agomelatin påvirker ikke frie koncentrationer af lægemidler, der binder med høj affinitet til plasmaproteiner eller omvendt.
Agomelatine does not modify free concentrations of medicinal products highly bound to plasma proteins or vice versa.
Agranulo- cytose(1)
Agranulocytosis(1)
Agranulocytose
granulocytopaenia
agranulocytose (et stærkt nedsat antal hvide blodlegemer) hæmolytisk anæmi (nedsat antal røde blodlegemer på grund af abnorm nedbrydning)
agranulocytosis (a severely lowered number of white blood cells) haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown)
Agranulocytose (inklusive hos spæ dbørn, der har væ ret eksponeret for infliximab i uterus), trombotisk trombocytopenisk purpura, pancytopeni, hæ molytisk anæ mi, idiopatisk trombocytopenisk purpura.
Agranulocytosis (including infants exposed in utero to infliximab), thrombotic thrombocytopenic purpura, pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.
Agranulocytose Eosinofili
Agranulocytosis Eosinophilia
Agranulocytose, anæmi, leukocytopeni, trombocytopeni, neutropeni
Agranulocytosis, anaemia, leukocytopenia, thrombocytopenia, neutropenia
Agranulocytose, knoglemarvsdepression
Agranulocytosis, bone marrow depression
Agranulocytose, knoglemarvssvigt
Agranulocytosis, bone marrow failure
agranulocytose, pancytopeni
agranulocytosis, pancytopenia
agranulocytose1,
agranulocytosis1,
Agranulocytosec, neutropeni, forhøjet eosinofiltal
agranulocytosisc, neutropenia, eosinophil count increased
Ahmedabad – 382213 Gujarat, Indien
Ahmedabad – 382213 Gujarat, India
aHUS-studie C10-004
aHUS Study C10-004
aHUS-studie C10-004 (N = 41)
aHUS Study C10-004 (N = 41)
aHUS: ema.europa.eu/Find medicine/Human medicines/Rare disease designations Dette sammendrag blev sidst ajourført i 10-2015.
aHUS: ema.europa.eu/Find medicine/Human medicines/Rare disease designations This summary was last updated in 10-2015.
aHvert brev indeholder 50 mg REYATAZ
aEach sachet contains 50 mg of REYATAZ
AI424-397 (PRINCE I): Hos pædiatriske patienter fra 3 måneder til under 6 år
AI424-397 (PRINCE I): In pediatric patients from 3 months to less than 6 years of age
AI424-451 (PRINCE II): Hos pædiatriske patienter fra 3 måneder til under 11 år
AI424-451 (PRINCE II): In pediatric patients from 3 months to less than 11 years of age
AI444042 og AI444010 var randomiserede, dobbeltblinde studier, som undersøgte daclatasvirs sikkerhed og virkning i kombination med peginterferon alfa og ribavirin (pegIFN/RBV) til behandling af kronisk HCV-infektion hos behandlingsnaive voksne med kompenseret leversygdom (herunder cirrose).
AI444042 and AI444010 were randomised, double-blind studies that evaluated the efficacy and safety of daclatasvir in combination with peginterferon alfa and ribavirin (pegIFN/RBV) in the treatment of chronic HCV infection in treatment-naïve adults with compensated liver disease (including cirrhosis).
AIDS)
AIDS),
Aids-relateret Kaposis sarkom
AIDS-related Kaposi’s sarcoma
AIDS-relateret Kaposis sarkom er sjælden hos kvinder.
AIDS-related Kaposi’s sarcoma is infrequent in women.
AIDS-relateret Kaposis sarkom er sjælden I denne population.
AIDS-related Kaposi’s sarcoma is infrequent in this population.
Aids-relateret Kaposis sarkom:
AIDS-related Kaposi’s sarcoma
AIDS-relateret KS-program
AIDS-related KS program
Airexar Spiromax 50 mikrog/500 mikrog Inhalationspulver.
Aerivio Spiromax 50 micrograms/500 micrograms Inhalation powder
Airexar Spiromax 50 mikrogram/500 mikrogram inhalationspulver
Aerivio Spiromax 50 microgram/500 microgram inhalation powder